Reduced Enterohepatic Recirculation of Mycophenolate and Lower Blood Concentrations are Associated with the Stool Bacterial Microbiome After Hematopoietic Cell Transplantation.

[1]  Ana Rita Brochado,et al.  Bioaccumulation of therapeutic drugs by human gut bacteria , 2021, Nature.

[2]  T. van Gelder.  How cyclosporin reduces mycophenolic acid exposure by 40% while other calcineurin inhibitors do not. , 2021, Kidney international.

[3]  Michael R. Taylor,et al.  Gut microbiota profiles and fecal beta‐glucuronidase activity in kidney transplant recipients with and without post‐transplant diarrhea , 2021, Clinical transplantation.

[4]  T. Kuwahara,et al.  Parabacteroides distasonis: intriguing aerotolerant gut anaerobe with emerging antimicrobial resistance and pathogenic and probiotic roles in human health , 2021, Gut microbes.

[5]  R. Paredes,et al.  Associations of the gut microbiome and clinical factors with acute GVHD in allogeneic HSCT recipients. , 2020, Blood advances.

[6]  Bahar Javdan,et al.  Personalized Mapping of Drug Metabolism by the Human Gut Microbiome , 2020, Cell.

[7]  J. Kanda,et al.  Drug monitoring for mycophenolic acid in graft‐vs‐host disease prophylaxis in cord blood transplantation , 2020, British journal of clinical pharmacology.

[8]  S. Paczesny,et al.  Biomarkers for Allogeneic HCT Outcomes , 2020, Frontiers in Immunology.

[9]  A. Koh,et al.  The gut microbiota in transplant patients. , 2020, Blood reviews.

[10]  A. Khoruts,et al.  Levaquin gets a pass. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  Patrick D Schloss,et al.  Reintroducing mothur: 10 Years Later , 2019, Applied and Environmental Microbiology.

[12]  A. Goodman,et al.  Insights from pharmacokinetic models of host-microbiome drug metabolism , 2019, Gut microbes.

[13]  Michael R. Taylor,et al.  Vancomycin relieves mycophenolate mofetil–induced gastrointestinal toxicity by eliminating gut bacterial β-glucuronidase activity , 2019, Science Advances.

[14]  A. Goodman,et al.  Mapping human microbiome drug metabolism by gut bacteria and their genes , 2019, Nature.

[15]  D. Fredricks.  The gut microbiota and graft-versus-host disease. , 2019, The Journal of clinical investigation.

[16]  Rohit Loomba,et al.  Microbiome 101: Studying, Analyzing, and Interpreting Gut Microbiome Data for Clinicians , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  Matthew R. Redinbo,et al.  Three structurally and functionally distinct β-glucuronidases from the human gut microbe Bacteroides uniformis , 2018, The Journal of Biological Chemistry.

[18]  Luke R. Thompson,et al.  Best practices for analysing microbiomes , 2018, Nature Reviews Microbiology.

[19]  Peer Bork,et al.  Extensive impact of non-antibiotic drugs on human gut bacteria , 2018, Nature.

[20]  M. Brink,et al.  Gut microbiota injury in allogeneic haematopoietic stem cell transplantation , 2018, Nature Reviews Cancer.

[21]  M. Redinbo,et al.  An Atlas of β-Glucuronidases in the Human Intestinal Microbiome. , 2017, Structure.

[22]  Xiaowei Zhan,et al.  Antibiotic-Induced Depletion of Anti-inflammatory Clostridia Is Associated with the Development of Graft-versus-Host Disease in Pediatric Stem Cell Transplantation Patients. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  J. McCune,et al.  Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II , 2016, Clinical Pharmacokinetics.

[24]  Y. Taur,et al.  Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  M. Perales,et al.  Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  S. Rampelli,et al.  Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT , 2015, Bone Marrow Transplantation.

[27]  N. Kadowaki,et al.  Monitoring mycophenolate mofetil is necessary for the effective prophylaxis of acute GVHD after cord blood transplantation , 2015, Bone Marrow Transplantation.

[28]  C. Staatz,et al.  Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update , 2014, Archives of Toxicology.

[29]  Daniel Wolff,et al.  Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  B. Sandmaier,et al.  Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[31]  T. Shokati,et al.  A high-throughput U-HPLC-MS/MS assay for the quantification of mycophenolic acid and its major metabolites mycophenolic acid glucuronide and mycophenolic acid acyl-glucuronide in human plasma and urine. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[32]  Baris E. Suzek,et al.  The Universal Protein Resource (UniProt) in 2010 , 2009, Nucleic Acids Res..

[33]  E. Deconinck,et al.  Pharmacokinetics of mycophenolic acid administered 3 times daily after hematopoietic stem cell transplantation with reduced-intensity regimen. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[34]  J. Wagner,et al.  Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation , 2009, Bone Marrow Transplantation.

[35]  S. Duncan,et al.  Distribution of beta-glucosidase and beta-glucuronidase activity and of beta-glucuronidase gene gus in human colonic bacteria. , 2008, FEMS microbiology ecology.

[36]  R. Borrows,et al.  The Magnitude and Time Course of Changes in Mycophenolic Acid 12-Hour Predose Levels During Antibiotic Therapy in Mycophenolate Mofetil-Based Renal Transplantation , 2007, Therapeutic drug monitoring.

[37]  Peter D. Karp,et al.  MetaCyc: a multiorganism database of metabolic pathways and enzymes , 2005, Nucleic Acids Res..

[38]  D. Weisdorf,et al.  Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation , 2005, Clinical pharmacology and therapeutics.

[39]  R. Borrows,et al.  Determinants of Mycophenolic Acid Levels After Renal Transplantation , 2005, Therapeutic drug monitoring.

[40]  E. Heinzen,et al.  The Influence of Norfloxacin and Metronidazole on the Disposition of Mycophenolate Mofetil , 2005, Journal of clinical pharmacology.

[41]  Y. Benno,et al.  Comparison of Four Microbial Enzymes in Clostridia and Bacteroides Isolated from Human Feces , 2002, Microbiology and immunology.

[42]  M. Hale,et al.  Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. , 1996, Transplantation proceedings.

[43]  J. Hasselström,et al.  Morphine Pharmacokinetics and Metabolism in Humans , 1993, Clinical pharmacokinetics.

[44]  K. R. Clarke,et al.  Non‐parametric multivariate analyses of changes in community structure , 1993 .

[45]  J. McCune,et al.  Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I , 2015, Clinical Pharmacokinetics.

[46]  C. Staatz,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients , 2007, Clinical pharmacokinetics.

[47]  V. Armstrong,et al.  Validation of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for free and total mycophenolic acid. , 2004, Clinical chemistry.

[48]  J. L. Martindale.  Subtle enablers. , 1984, The Journal of the Arkansas Medical Society.